AzurRx (AZRX) Corporate Media Kit

23 Trial conducted in France, Australia and New Zealand; 11 patients enrolled (C) Open-label phase 12-15 days each step (D) Follow-up 12-15 days (A) Screening 0-30 days (B) Washout 12-15 days Usual PPE treatment Previous PPE treatment Screening MS1819-SD 2240mg/day Baseline MS1819-SD 280mg/day MS1819-SD 560mg/day MS1819-SD 1120mg/day Inclusion V1 V2 V3 V4 V5 V6 V7 V8 Fecal elastase-1 at screening <100 µg/g Inpatient CFA measurement (mean of 3 consecutive days) Outpatient CFA measurement (mean of 3 consecutive days) 120 days N = 11 patients Multi-Center Trial Sites (France, Australia, NZ) Clinical Trial Design for MS1819 Phase 2 in Chronic Pancreatitis